COMMUNIQUÉS West-GlobeNewswire

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated 2022, supporting [...]
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
11/06/2025
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company [...]
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated in 2022, supporting [...]
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
11/06/2025
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated therapeutics to [...]
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
11/06/2025
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a [...]
Elkedonia clôture un tour d’amorçage de 11 millions d’euros pour le développement de neuroplastogènes comme traitements novateurs contre la dépression et les troubles neuropsychiatriques
11/06/2025
Les fonds permettront d’avancer dans la découverte de traitements potentiellement disruptifs, à action rapide, pour la dépression résistante aux traitements et d'autres troubles neuropsychiatriques. Molécules « first-in [...]
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders
11/06/2025
Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders First-in-class, non-addictive, non-hallucinogenic molecules with a non- [...]
Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
11/06/2025
Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs First start-up company from Argobio’s portfolio to reach [...]
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
11/06/2025
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle (Saale) / Munich, Germany, June 11 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les crises d'épilepsie chez l'enfant
11/06/2025
Communiqué de presse CROSSJECT avance sur le développement de ZEPIZURE® Junior , sa solution pour les crises d'épilepsie chez l'enfant Annonce la calibration réussie de ZENEO® pour l'utilisation de ZEPIZURE® dans la [...]
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
11/06/2025
Press release CROSSJECT advances on the development of ZEPIZURE® Junior , its solution for epilepsy crises in children Announces the effective calibration of ZENEO ® for the use of ZEPIZURE ® in the pediatric population [...]
ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights
11/06/2025
EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and [...]
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
11/06/2025
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE [...]
Persica strengthens global IP portfolio with EU patent granted for PP353
11/06/2025
London, UK, 11 June 2025 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been [...]
Telescope Innovations’ Directors Establish Private Debt Instrument to Accelerate Development of Self-Driving Labs
11/06/2025
VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) -- Telescope Innovations Corp. (“Telescope Innovations”, “Telescope”, or the “Company”) (CSE: TELI) (OTCQB: TELIF) (FSE:4JU) is a leader in intelligent [...]
BrightSpring Announces Pricing of Secondary Offering of Common Stock
11/06/2025
LOUISVILLE, Ky., June 10, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
10/06/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 10 juin 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
10/06/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, June 10, 2025 (GLOBE NEWSWIRE [...]
Celularity Announces Chief Financial Officer Transition
10/06/2025
Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period FLORHAM PARK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU [...]

Pages